Renalytix Share Discussion Threads

[wan] 31/3/2020 07:35

Renalytix AI plc is being highlighted as a successful AIM story by the London Stock Exchange -

An IPO on AIM helped Renalytix secure their long-term health

RenalytixAI's diagnostic products could change the lives of millions who suffer from kidney disease. Joining AIM has been central to the strategy of this emerging growth company.

[dazzerman4] 27/3/2020 07:26

Renalytix AI PLC Presentation of KidneyIntelX Health Economics DataSource: RNS Non-RegulatoryTIDMRENXRenalytix AI PLC27 March 2020Renalytix AI plc("RenalytixAI", the "Company") Presentation of KidneyIntelX(TM) Health Economics Data Renalytix AI plc (LSE : RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that further to RNS Reach 2937H on 24 March 2020, Boston Healthcare Associates has presented data on KidneyIntelX(TM) , the Company's AI-enabled in vitro diagnostic test for kidney disease, and the clinical and health economic benefit from deploying the test in large health systems in the United States during National Kidney Foundation's Spring Clinical Meeting.A poster summarizing the data presented by Boston Healthcare is now available through the conference website and at https://renalytixai.com/investors/utility-and-impact-of-kidneyintelx .It is estimated that there are 12 million individuals with diabetic kidney disease (DKD) in the United States alone. The economic impact model estimates that KidneyIntelX(TM) testing of 100,000 individuals with DKD, with the assumption of a 20% relative decrease in DKD progression for the 16% of DKD individuals scored as "high-risk" by KidneyIntelX(TM) patients, could deliver cumulative savings of more $1 billion over a five-year period. The presentation was delivered by Thomas Goss, PharmD, Senior Vice President, Boston Healthcare Associates.During the presentation, Dr. Goss described the population health benefits that can be realized with system-wide adoption of KidneyIntelX(TM) . These include delaying progression to more advanced stages of DKD, reducing hospitalizations, and avoiding unplanned emergency room crashes onto dialysis, and delaying or preventing end stage kidney disease, and related dialysis and kidney transplant procedures. These outcomes will not only lead to a significant improvement in quality of life for diabetic kidney disease patients, they also can drive significant cost benefit for health providers and insurers. The model developed by Boston Healthcare demonstrates that a health insurer will realize net savings in less than two years, assuming a one-time use of the test. Based on 100,000 patients tested, annual savings increase each year and peak at $685 million in year five. This combination of significantly improved patient outcomes, optimal utilization of healthcare resources, and savings for health insurers is expected to lead to an increase in coverage determinations for KidneyIntelX(TM) from private insurers in the United States in both 2020 and 2021.NKF's Spring Clinical Meeting gathers more than 3,000 nephrology healthcare professionals from across the United States to learn about the newest developments related to all aspects of nephrology practice. Due to the coronavirus and coronavirus disease (COVID-19) outbreak in the United States the meeting is being held as a live virtual event in 2020. Sessions can be accessed through the conference website. For information about the NKF's virtual conference event, visit https://www.kidney.org/spring-clinical .

[pugugly] 21/3/2020 13:34

Being a realist cynic - If those with kidney problems have a very significanly higher risk profile of dying from the virus might not much of the potential market be removed?

OK- PI but likely?

[toffeeman] 21/3/2020 13:22

This post is a test as the thread seems to be suck - so please ignore

[dazzerman4] 19/3/2020 00:38

AI testing on covid 19

[wan] 10/3/2020 16:10

The Presentation(March 2020)from last week in the US and last night in the UK, is now available on the Renalytix website -

[wan] 03/3/2020 08:00

All other positive developments and progress aside, I was not expecting the potential spin-out and admission to AIM of FractalDX, which could deliver further value.

Future developments and outlook section provides an insightful read and the following excerpt is ringing loud in my ears -

"We continue to believe that the macro environment for kidney disease has undergone disruptive positive change in the past year. Our own market-based experience has suggested an increasing level of urgency from large medical stakeholders to improve diagnosis and prognosis in earlier stages of kidney disease (stages 1, 2 and 3) for better health economics and patient outcomes."

[wan] 26/2/2020 07:18

And on the same date as the Presentation in the US, Renalytix will release its interim results for the six months ended 31 December 2019, on Tuesday 3 March 2020.

Put another way, a US and UK investor Results briefing.

Renalytix gets a strong mention in CNBC article -

A major breakthrough for the millions of Americans on the brink of kidney failure and dialysis
PUBLISHED TUE, FEB 25 2020

KEY POINTS
RenalytixAI has developed an artificial intelligence clinical diagnostic that rates a person’s chances of getting kidney disease.

The tool, called KidneyIntelX, is expected to launch in the second quarter of this year.

The company has also developed FractalDX, a lab-based AI tool that can predict the risk of adverse transplant outcomes, including early kidney rejection.

The U.S. spends about $100 billion annually to treat the nearly 40 million Americans suffering from chronic kidney disease who need dialysis and organ transplants.

Medical experts are hoping 2020 will mark a turning point in the fight against kidney disease in America, thanks to advancing technology. Currently, the U.S. spends about $100 billion annually to treat the nearly 40 million Americans suffering from chronic kidney disease who need dialysis and organ transplants. The public health crisis, exacerbated by the rise in obesity and type 2 diabetes, is now the ninth leading cause of death in the nation, according to the Centers for Disease Control and Prevention.

One company making inroads in the field is RenalytixAI, an AI clinical diagnostics company for kidney disease. It has received an FDA breakthrough device designation for its KidneyIntelX, an AI-powered diagnostic product for kidney disease that is expected to launch in the second quarter of this year in the U.S.

Full story -

[wan] 25/2/2020 07:41

Slightly intrigued that an announcement of a presentation was via an RNS as opposed to an RNS-Non-Regulatory.

Anyway, I look forward to the presentation on Tuesday 3 March, which will be made available on Renalytix website.

[wan] 19/2/2020 08:16

According to a new paper, Kidney disease risk reduced by SGLT2 inhibitors.

RenalytixAI’s solutions are being designed to make significant improvements in kidney disease risk assessment, clinical care and patient stratification for drug clinical trials.

KidneyIntelX will thus be of particular interest to large pharma's efforts in terms of supporting the use of SGLT2 inhibitors to prevent major kidney outcomes in people with type 2 diabetes(as well as patient stratification for drug clinical trials).


18 FEBRUARY 2020
In type 2 diabetes, SGLT-2 inhibitors reduce risk for major kidney outcomes

[wan] 19/2/2020 08:04

Further evidence supporting screening of at risk groups (and potentially beyond) -

Almost half of over-60s with CKD are undiagnosed, research suggests
18 February 2020

Almost half of over-60s with chronic kidney disease may be undiagnosed, according to new research.

In response, there 'could be value' in checking kidney function in patients with conditions such as hypertension or diabetes.

Primary care researchers in Oxford have found that the prevalence of CKD in people aged over 60 is around 18% and that almost half of these patients would be undiagnosed without screening.

Full story -

[dazzerman4] 17/2/2020 16:16

Waiting for some positive news on this one anytime now

[wan] 14/2/2020 08:40

Edit...I have also included the FractalDX portfolio for kidney transplant rejection to the above post, as formal launch as a laboratory developed test through Renalytix New York City clinical laboratory facility is expected in 2020.

[wan] 14/2/2020 08:00

Important findings given the national attention being applied to kidney care delivery and efforts of the current US administration to improve kidney care -

The Journal of the American Society of Nephrology
February 2020
Measuring Quality in Kidney Care: An Evaluation of Existing Quality Metrics and Approach to Facilitating Improvements in Care Delivery

Significance Statement
Leveraging quality metrics can be a powerful approach to improve patient outcomes. However, the validity of existing kidney-related quality metrics is unknown. To identify whether existing measures can effectively address and guide quality improvement in care of patients with kidney disease, the American Society of Nephrology’s Quality Committee performed a systematic compilation and evaluation of national kidney metrics. They identified 60 metrics, rating only 29 as highly valid and the other 31 metrics as of medium to low validity, on the basis of defined criteria. Almost half of the measures were related to dialysis management, compared with only one metric related to kidney replacement planning and two related to patient-reported outcomes. The authors urge refinement of existing quality metrics and development of new measures that better reflect kidney care delivery.

Conclusions
We rated less than half of kidney disease quality metrics as highly valid; the others fell short because of unclear attribution, inadequate definitions and risk adjustment, or discordance with recent evidence. Nearly half of the metrics were related to dialysis management, compared with only one metric related to kidney replacement planning and two related to patient-reported outcomes. We advocate refining existing measures and developing new metrics that better reflect the spectrum of kidney care delivery.



Cue Renalytix KidneyIntelX and the FractalDX portfolio

[wan] 14/2/2020 07:45

Edit...Important "in conclusion" paragraph added to above post.

[the stigologist] 30/1/2020 10:01

Exscientia a $1bn Unicorn seems the closest comparitor to ETX

ETX at £10m Mkt Cap looks incredibly undervalued to me

[wan] 30/1/2020 07:29

A very good article from one of the co-founders -

January 28, 2020
Diabetes Epidemic Continues to Grow, Stressing the Need for Earlier CKD Diagnosis
Steven G. Coca, DO

I began practicing and treating patients with chronic kidney disease (CKD) more than 12 years ago. As my career in nephrology has progressed, CKD has also progressed and is one of the most critical public health challenges in the United States and worldwide. The statistics are daunting: currently, there are 850 million individuals with CKD worldwide,1 with 37 million in the United States.2

Along with the effect on patients, CKD and DKD have a tremendous effect on the nation’s healthcare system. Approximately 20% of dollars in traditional Medicare — $114 billion in 2018 — are spent on Americans with kidney disease.11,12 The United States Renal Data System (USRDS) has stated that kidney disease is a cost multiplier, as its accompanying conditions, such as diabetes and heart failure, increase the cost of caring for individuals with CKD. The organization asserts that there could be substantial cost savings if these diseases are detected and treated early, which would prevent further complications.10

Given the increasing prevalence of diabetes and CKD, as well as the effect CKD has and will continue to have on patients and the healthcare system, it is more important now than ever for healthcare providers to have the ability to detect kidney disease at its earliest stages. Early and accurate risk stratification of individuals likely to experience rapid kidney function decline or kidney failure is critical for improving patient outcomes, clinical resource allocation, and cost control.

How AI Can Make an Impact on CKD and DKD
On July 10, 2019, President Trump launched the Advancing American Kidney Health Initiative directing the Department of Health and Human Services (HHS) to take bold action to transform how kidney disease is prevented, diagnosed, and treated in the next decade.13 Administration officials from HHS, the Centers for Medicare and Medicaid Services, the US Food and Drug Administration, the US Centers for Disease Control and Prevention, and other federal agencies have defined 3 goals for improving kidney health. The first goal is to reduce the number of Americans developing ESRD by 25% by 2030.13

One of the most promising methods for enabling healthcare providers to identify and properly stratify risk for patients likely to experience fast-progressing kidney disease or advance to kidney failure is artificial intelligence (AI) combined with electronic health records and biomarkers.

Full story -

[wan] 27/1/2020 07:54

The Artificial Intelligence (AI) opportunity across biopharma and diagnostics is very large indeed.

The use of AI in drug development is particularly promising and look set to accelerate all aspects of drug development, there is also a cross-over to diagnostics, with risk assessments and companion diagnostics also becoming increasingly integral in terms of patient stratification for drug clinical trials and clinical care. Hence large pharma are increasingly active across the AI biopharma and diagnostics space.

Subsequently, AI in healthcare will continue to see very healthy levels of partnering and deal activity.

Renalytix is well advanced in terms of development and executing its commercial strategy (without Sensyne) and are thus extremely well placed to enable improved diagnostic solutions for kidney disease, with significant improvements in kidney disease risk assessment, clinical care and patient stratification for drug clinical trials.

Therefore, Renalytix are well placed to address one of the most common and costly chronic medical conditions globally.

[wan] 08/1/2020 07:43

Great news and delivery of a strategic initiative!

Renalytix previously stated that "The Company also expects additional strategic initiatives to be implemented which will further expand distribution and accessibility for KidneyIntelX™. These additional strategic initiatives will be announced in the coming months as appropriate." (Which is plural)

Clearly today's news of a new laboratory that enables five-fold test volume increase, is 'one' such strategic initiative! The New York lab will be certified shortly as planned.

The statement that the increase in maximum potential processing capacity to approximately 15,000 reportable test results per month across both sites also provided significant risk mitigation through operational redundancy, indicates the significant level of demand expected.

With more news flow to come, along with rapid revenue build, 2020 indeed looks to set to be a catalyst year!

[wan] 06/1/2020 07:55

Renalytix recent tweet (3rd Jan) is interesting, especially when considered in the context of my post 112 above -

The two main causes of CKD are diabetes and high blood pressure. These two conditions were responsible for nearly 75% of kidney failure cases between 2014–2016.

[wan] 03/1/2020 07:42

I note today's update, plus Renalytix tweeted - 2020 is going to be a big year for KidneyIntelX -